- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
November 11, 2024Tommy Du Honored With 2024 Sheila Sonenshine Associate Pro Bono Award
-
December 3, 2024Can You Keep a Secret? Privacy Laws and Civil Litigation
-
December 4, 2024Trust & Estate Litigation in Minnesota
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
November 6, 2024How Recent Patent Damages Precedent May Increase Reasonable Royalty Awards
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches Q1 2012
Reference Listed Drug, NDA Holder, Generic Drug Name, ANDA Applicant(s), Indication and Launch Date
April 04, 2012
| Reference Listed Drug | NDA Holder | Generic Drug Name | ANDA Applicant(s) | Indication | Launch Date |
|---|---|---|---|---|---|
| Yaz | Bayer HealthCare Pharmaceuticals Inc.'s | Vestura(TM) (3 mg drospirenone and 0.02 mg ethinyl estradiol) | Watson Pharmaceuticals | prevention of pregnancy and for the treatment of moderate acne in women | Jan. 18, 2012 |
| Zanaflex | Watson Pharmaceuticals | tizanidine hydrochloride capsules | Acorda Therapeutics, | short-acting drug indicated for the management of spasticity. | Feb. 6, 2012 |
| Zanaflex | Acorda Therapeutics | tizanidinehydrochloride | Apotex | Multiple sclerosis skeletal muscle relaxants | Feb. 9, 2012 |
| Lexapro | Forest Laboratory | Escitalopram Tablets USP, 5 mg, 10 mg and 20 mg | Mylan Pharmaceuticals Inc. | depression and generalized anxiety disorder treatment | Feb. 29, 2012 |
| Geodon | Pfizer Inc.'s | ziprasidone | Dr. Reddy's Laboratories | antipsychotic drug | Mar. 2, 2012 |
| Prometrium | Abbott Laboratories | Progesterone Capsules, 100 & 200 mg | Teva Pharmaceutical Industries Ltd. | secondary amenorrhea due to a decrease in progesterone as well as in conjunction with estrogen-containing medications in postmenopausal women with a uterus. | Mar. 2, 2012 |
| Prometrium | Abbott Laboratories | Progesterone Capsules, 100 & 200 mg | Watson Pharmaceuticals | secondary amenorrhea due to a decrease in progesterone as well as in conjunction with estrogen-containing medications in postmenopausal women with a uterus. | Mar. 2, 2012 |
| Geodon | Pfizer Inc.'s | ziprasidone | Lupin Pharmaceuticals | antipsychotic drug | Mar. 3, 2012 |
| Lexapro | Forest Laboratory | Escitalopram Oxalate Tablets | Teva Pharmaceutical Industries Ltd. | depression and generalized anxiety disorder treatment | Mar. 14, 2012 |
| Lexapro | Forest Laboratory | Escitalopram Oxalate Tablets | Amneal Pharmaceuticals | depression and generalized anxiety disorder treatment | Mar. 15, 2012 |
| Seroquel | AstraZeneca | quetiapine fumarate tablets | Teva Pharmaceutical Industries Ltd. | antidepressants in major depressive disorder and acute depressive episodes in bipolar disorder | Mar. 28, 2012 |
| Seroquel | AstraZeneca | quetiapine fumarate tablets | Mylan Pharmaceuticals Inc. | antidepressants in major depressive disorder and acute depressive episodes in bipolar disorder | Mar. 28, 2012 |
GENERICally Speaking Spring 2012
Related Publications
September 18, 2024
Astellas Pharma, Inc. v. Sandoz Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 9, 2024
Purdue Pharma L.P v. Accord Healthcare Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 4, 2024
Exeltis USA, Inc. v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
August 28, 2024
Teva Branded Pharm. Products R&D, Inc. v. Deva Holding A.S.
GENERICally Speaking Hatch Waxman Bulletin
August 13, 2024
Allergan USA, Inc. v. MSN Labs. Private Ltd.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.